The company is making its mark through strategic initiatives, promising to become a significant presence in the evolving pharmaceutical sector
Winrevair is the first activin signaling inhibitor therapy for PAH approved in Europe
FDA has concluded that this inspection is 'closed'
WINREVAIR is a breakthrough biologic for this rare, progressive disease
The first and only oral androgen deprivation therapy treatment for men with advanced prostate cancer
Express Scripts to add Zepbound to National Preferred Formulary
Likmez oral suspension is the first and only FDA-approved liquid option for patients with adherence hurdles such as dysphagia, difficulty swallowing
he company posted total income during Q2 FY24 at Rs. 12.86 crore
The launch of HULIO in the United States is an important milestone for Biocon Biologics
The company will supply materials to all global regions including Asia such as China, India, Europe, and the U.S.
Subscribe To Our Newsletter & Stay Updated
